Understand · Treat · Recover

Locally Advanced Head & Neck Cancer

Locally advanced disease often needs combined treatment and can still be treated with curative intent.

Patient education only. This guide does not diagnose cancer or prescribe treatment. Your team must adapt decisions to your cancer, health, preferences and local resources.

All 25 chapters

Chapter 18 of 25

Resectable, unresectable and functional questions

Locally advanced cancer has grown substantially at its starting site, spread to regional lymph nodes, or both, without necessarily spreading to distant organs. Resectable means a specialist surgical team believes it can be removed with acceptable cancer clearance and consequences. Unresectable disease may still be approached with definitive radiation-based treatment when appropriate.

The decision includes expected function. A severely damaged larynx with unsafe swallowing may not benefit from an organ-preservation approach in the same way as a functional voice box. Major cartilage destruction, extent into surrounding tissues, aspiration and the ability to tolerate treatment all matter. A tumour board should discuss both cancer control and life after treatment.

Surgery followed by risk-adapted treatment

Many resectable locally advanced oral cavity cancers are treated with surgery and appropriate neck management, followed by treatment guided by the final pathology. Radiation may be recommended for features such as advanced tumour extent, nodal involvement, perineural invasion or other risks. The exact combination of findings matters.

Positive margins mean cancer reaches a cut edge. Extranodal extension means cancer has grown outside a lymph node. These are major reasons to consider postoperative radiation with concurrent cisplatin in a suitable patient. Re-resection may be discussed for an involved margin if feasible. RTOG 9501 and EORTC 22931 compared postoperative radiation with or without cisplatin in high-risk resected squamous cancer; they underpin this combined-treatment approach, especially for positive margins and extranodal extension.

An updated combined analysis in 2025 supports considering overall recurrence risk and treatment fitness rather than treating margins and extranodal extension as perfect predictors of who benefits. The added cancer-control benefit must be balanced against treatment harm. This does not mean every postoperative patient needs chemotherapy.

Definitive chemoradiotherapy and organ preservation

Definitive chemoradiotherapy is commonly used for selected oropharyngeal, laryngeal and hypopharyngeal squamous cancers. It combines radiation to the primary and relevant nodal regions with a radiosensitizing medicine, often cisplatin. It avoids upfront removal of the organ in suitable cases, but can still cause long-term swallowing or voice problems.

Surgery remains important for selected bulky laryngeal disease, a poorly functioning larynx, persistent disease or recurrence. People who cannot tolerate concurrent chemotherapy need an individualized alternative; options may include radiation alone or another evidence-supported regimen. The appropriate choice is not determined by age alone.

Induction chemotherapy: a selected tool

Induction treatment precedes definitive local treatment. A docetaxel, cisplatin and 5-FU combination may be used in selected specialist pathways, such as larynx preservation. Induction is not a routine extra step for every mucosal squamous cancer and may add toxicity or delay radiation if used without a clear plan.

Nasopharyngeal carcinoma is a distinct disease in which induction chemotherapy has stronger evidence for selected locoregionally advanced cases. Its regimens and selection criteria should not be transferred wholesale to oral cavity cancer. Ask what specific question induction is intended to answer and when definitive treatment will begin.

Perioperative pembrolizumab

KEYNOTE-689 tested a planned course beginning before surgery and continuing after surgery alongside risk-adapted postoperative treatment. It improved event-free survival compared with surgery and standard postoperative treatment alone. United States FDA approval requires PD-L1 CPS of at least 1 in eligible adults with resectable locally advanced squamous cancer.

The regimen does not remove the need for adequate surgery, timely radiation or cisplatin when indicated. It is not automatically appropriate for all locally advanced tumours, all HPV groups or people with major immune-related contraindications. Local regulatory approval and the current guideline pathway must be checked before offering it.

NIVOPOST-OP: what the evidence does and does not say

The phase III NIVOPOST-OP study, published in The Lancet in 2026, compared postoperative cisplatin-radiotherapy with or without added nivolumab in high-risk resected head and neck squamous cancer. Disease-free survival improved, with an increase in toxicity. This is published randomized evidence rather than merely a preliminary idea.

However, a positive publication is different from a country-specific drug approval, guideline adoption or reimbursement decision. This guide does not assert universal approval or confirmed Indian adoption. The treating team should verify those points and discuss how the patient matches the trial population. NIVOPOST-OP is a postoperative strategy; KEYNOTE-689 begins before surgery. They should not be combined or substituted without evidence.

Keep supportive care alongside treatment

Dental preparation, pain control, nutrition, swallowing support and transport planning help patients complete treatment. Response is assessed at an appropriate interval because inflammation immediately after radiation can confuse scans. New breathing difficulty, major bleeding or inability to swallow fluids requires urgent assessment rather than waiting for a routine response scan.

References and evidence review

Evidence/editorial check: 25 October 2026. AI-assisted preparation is distinct from individual physician review. See the linked review policy for source-access limits and review status. Regulatory indications, reimbursement and availability vary by country. Trial results alone do not establish approval everywhere; your treating team should confirm the applicable current guidance.